- Oops!Something went wrong.Please try again later.
DGAP-News: MagForce AG / Key word(s): Miscellaneous
MagForce AG Supports World Brain Tumor Day and Informs about Various Patient Events to Raise Awareness for One of the Deadliest Oncological Indications
Berlin, Germany, and Nevada, USA, June 7, 2021 - MagForce AG (Frankfurt, Scale, Xetra: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, offering the NanoTherm Therapy System for the treatment of brain tumors, supports World Brain Tumor Day on June 8th, 2021 and informs about various virtual patient events to raise awareness for this devastating disease.
"Though rare compared to other types of cancers, brain tumors, especially glioblastomas, are a devastating and mostly fatal disease. Despite major advances in treatment modalities, malignant tumors of the brain remain largely incurable and an unresolved therapeutic problem. At MagForce it is our mission to provide patients with a further treatment option and make our innovative approach based on nanotechnology available all over the world," said Ben Lipps, CEO of MagForce AG and MagForce USA, Inc. "Keeping in line with tradition, I am happy that MagForce once again has the opportunity to support affiliated brain tumor centers in their numerous activities for brain tumor patients and their caregivers on occasion of the World Brain Tumor Day."
Zwickau, Germany - Paracelsus Clinic Zwickau Hosts Patient Hotline "Meet a Professor"
In 2019, the Paracelsus Clinic Zwickau and MagForce announced their cooperation on the occasion of 20th anniversary of the World Brain Tumor Day, one of four clinics in Europe to offer MagForce's NanoTherm Therapy System for the treatment of brain tumors. Headed by Prof. Dr. med. habil. Jan-Peter Warnke, the department of neurosurgery cares for approximately 2,200 patients annually and performs an average of 1,500 surgeries per year, of which approximately 300 are primary gliomas.
This year, the Paracelsus Clinic Zwickau will host an open hotline "Meet a Professor" where patients will be able to put forth any questions they may have regarding brain tumors and multiple treatment options. Prof. Dr. med. Habil. Warnke and Christian Schürer, Assistant Physician and contact for the NanoTherm Therapy System at the Paracelsus Clinic Zwickau, will be available from 9am to 3pm to answer questions on the subject of glioblastomas and the NanoTherm Therapy as an alternative treatment option.
When: Tuesday, June 8th, 2021, 9am-3pm CEST
Lublin, Poland - Alivia Cancer Foundation, SPSK4 Hospital and MagForce Invite you to join their Infoline on the Treatment of Brain Tumors Using the NanoTherm Therapy System
The Independent Public Clinical Hospital No. 4 (SPSK4) in Lublin, one of the leading brain treatment centers in Poland, is the first hospital outside of Germany to offer MagForce's NanoTherm Therapy System as an additional treatment option allowing Polish patients to receive treatment in their home country and provide faster access to the therapy for patients from surrounding countries.
On occasion of the 2021 World Brain Tumor Day, the SPSK4 will host a free Infoline, supported by MagForce and Alivia Cancer Foundation. Prof. Tomasz Trojanowski, Polish National Consultant for Neurosurgery and a member of the Scientific Advisory Board of the Minister of Health of Poland, Prof. Radoslaw Rola, Head and Chairman of the Neurosurgery and Paediatric Neurosurgery Departments, and Dr Jacek Woźniak, Specialist of the Center for Innovative Therapies, will be available for a free consultation and answer all patient question regarding the NanoTherm Therapy System at SPSK4.
When: Tuesday, June 8th at 9am-3pm (Dr. Jacek Woźniak) and 3pm-4pm CEST (Prof. Tomasz Trojanowski and Prof. Radoslaw Rola)
DGNC 2021, Virtual - MagForce is Main Sponsor of the Leading Conference in the Field of Neurosurgery
Taking place around the World Brain Tumor Day from June 6-9, the 72nd Annual Meeting of the German Society of Neurosurgery (DGNC) held jointly with the Polish Society of Neurosurgeons will provide a virtual platform to present scientific findings, discuss new innovative treatments and exchange information about the most recent research results and future visions.
As main-sponsor, MagForce is excited to support this important event in the field of neurosurgery and represented with a virtual booth, where MagForce representatives are available for questions regarding its NanoTherm Therapy System.
For more information on the 2021 DGNC Meeting programme, please click here.
About World Brain Tumor Day
Declared by the Deutsche Hirntumorhilfe (German Brain Tumour Association) in 2000 as an international commemoration day, the World Brain Tumor Day is celebrated every year on June 8th to raise awareness about brain tumours and inspire hope for patients living with this disease. According to current information from the Deutsche Hirntumorhilfe[i], each year, more than 8,000 people are diagnosed with a primary brain tumor in Germany alone. Glioblastoma is the most common and aggressive form of brain tumors in adults with an incidence, i.e. the number of new cases per year, of about three patients per 100,000 people. Worldwide, over 700 new cases are recorded on a daily basis. Additionally, many other types of cancer cause metastases in the brain, which are known as secondary brain tumors. Despite major advances in treatment modalities, malignant tumors of the brain remain largely incurable and an unresolved therapeutic problem.
The NanoThermTherapy System for the Treatment of Brain Tumors
MagForce's NanoTherm Therapy System provides a novel, nanotechnology-based approach for the treatment of solid tumors by introducing magnetic nanoparticles either directly into the tumor or into the resection cavity wall. At the discretion of the attending neurosurgeon, the NanoTherm liquid containing the magnetic nanoparticles can be instilled in the course of the tumor resection, keeping interventions to a minimum. The particles are subsequently heated by an alternating magnetic field that allows targeted treatment by irreparably destroying, or weakening, cancer cells making them more sensitive to concomitant radiotherapy or chemotherapy. These sessions generally take place over a three-week period, either in an in-patient or out-patient setting depending on the patients condition, and are nearly completely free of pain and discomfort. The limited time span required for the treatment makes the therapy highly predictable and allows the patient to return to everyday life and regain significant quality of life as far and as soon as possible. Since the particles remain at the site of instillation due to their special coating, the surrounding healthy tissue is spared and the integration into multimodal therapy concepts are made possible.
MagForce AG was granted the European CE certificate ("European Certification") and thus the official approval of the NanoTherm Therapy System for the treatment of brain tumors in Germany and all member states of the European Union.
About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the Scale segment of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group's proprietary NanoTherm therapy system enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(R) are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries.
[i] Deutsche Hirntumorhilfe, https://www.hirntumorhilfe.de/projekte/welthirntumortag1/
07.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
+49 (0)30 308 380 0
+49 (0)30 308 380 99
Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Scale), Stuttgart, Tradegate Exchange
EQS News ID:
End of News
DGAP News Service